



Company Announcement no. 13/2010

To: NASDAQ OMX Copenhagen

Hørsholm, Denmark, 18 August, 2010

## **LifeCycle Pharma announces result for the first half 2010 in line with expectations**

### **Major achievement in reaching agreement with FDA on the pivotal phase 3 study for LCP- Tacro™**

#### **Highlights:**

- LCP has entered into an agreement with the U.S. Food and Drug Administration (FDA) on a Special Protocol Assessment (SPA) of its pivotal Phase 3 study, for LCP-Tacro™ in patients, who have just received a kidney transplant (“de novo” transplant patients).
- Positive results have been obtained from a Phase 2 clinical trial for LCP-Tacro™ in de novo kidney transplant patients. These data confirm the previous positive experience with LCP-Tacro™ in stable kidney and liver transplant patients and support comparability of LCP's extended release tablet formulation of tacrolimus when compared to twice daily Prograf® capsules. Further, the results indicate that LCP-Tacro™ tablets may be safely and efficaciously administered once daily immediately following a kidney transplant.
- Edward E. Koval and Dr. John Weinberg have joined LCP's senior management team as Senior Vice President, Business Development and Strategic Corporate Development, and Senior Vice President, Commercial Development and Strategic Planning, respectively. Subsequently Johnny Stilou has been promoted to Chief Financial Officer.
- LCP reported a net loss of DKK 132.2 million for the first half of 2010 compared to a net loss of DKK 144.3 million for the same period in 2009. The reported net loss is in line with the expectations for 2010 which were announced in the annual report for 2009 published on 24 February, 2010.
- For the first half of 2010, LCP's research and development costs amounted to DKK 96.0 million compared to DKK 120.4 million during the same period in 2009.
- On 30 June, 2010, LCP had cash and cash equivalents of DKK 205.1 million.

William J Polvino, president and CEO said: “The SPA Agreement for LCP-Tacro™ pivotal phase 3 study is a very significant achievement for LCP. We have now received a formal green light from the FDA as to our proposed clinical study design and are now well-positioned to move forward with the study start. Further, we have achieved increased clarity on the costs and timing to regulatory approval. “

A conference call will be held today, 18 August, 2010 at 5:30 PM CET (Denmark). Please refer to page 7 for further details.



## Outlook for 2010

LCP maintains its 2010 outlook with an operating loss of DKK 260–290 million and likewise a net loss of DKK 260–290 million.

The Company's 31 December, 2010 cash position is expected to be in the range of DKK 50–100 million.

## Research & development update

### *LCP-Tacro™ in kidney patients (stable patients)*

The clinical Phase 3 program in stable kidney transplant patients was initiated in December 2008, and full patient enrollment was finalized early January 2010 with 326 patients. The clinical trial is progressing according to plan, and approx. 100 patients have currently completed their treatment. We expect as previously announced to complete the treatment in stable kidney patients in first quarter of 2011.

### *LCP-Tacro™ in kidney patients (de novo patients)*

As announced we have entered into an agreement with the U.S. Food and Drug Administration (FDA) on a Special Protocol Assessment (SPA) of the pivotal Phase 3 study, for LCP-Tacro™ in patients, who have just received a kidney transplant ("de novo" transplant patients).

The study is a randomized, double-blind, multicenter study that will compare once-daily LCP-Tacro™ against the current market leading comparator, twice-daily Prograf® in de novo kidney transplant patients. A 12-month treatment period will be followed by a 12-month blinded extension. The primary endpoint of the study will be to demonstrate the non-inferiority of LCP-Tacro™, compared to Prograf®, on kidney graft function (biopsy proven acute rejection, graft failure, death, or loss to follow up) at 12 months. Secondary endpoints will include safety, tolerability and renal function assessments. The study will be conducted at approximately 75-100 transplant centers, primarily in the United States and Europe, and entail the enrollment of 540 patients.

Study initiation is anticipated in the third quarter of this year.



**Key Figures**

	YTD 2010 DKK'000	YTD 2009 DKK'000	Q2 2010 DKK'000	Q2 2009 DKK'000	Year 2009 DKK'000
<b>Income Statement</b>					
Revenue	1,494	1,847	871	1,499	2,476
Research and development costs	(95,973)	(120,414)	(39,625)	(57,604)	(210,140)
Administrative expenses	(25,930)	(33,338)	(12,773)	(16,357)	(62,381)
One-off restructuring cost	(10,894)	-	-	-	(9,489)
Operating loss	(131,303)	(151,905)	(51,527)	(72,462)	(279,534)
Net financial income / (expenses)	(526)	7,630	(313)	(2,105)	8,540
Loss before tax	(131,829)	(144,275)	(51,840)	(74,567)	(270,994)
Tax for the period	(395)	-	(395)	-	-
Net loss for the period	(132,224)	(144,275)	(52,235)	(74,567)	(270,994)
<b>Balance Sheet</b>					
Cash and cash equivalents	205,136	439,809	205,136	439,809	333,429
Total assets	245,345	500,455	245,345	500,455	379,269
Share capital	56,568	56,439	56,568	56,439	56,568
Total equity	189,958	436,727	189,958	436,727	317,281
Investment in property, plant and equipment	594	9,664	101	7,149	11,043
<b>Cash Flow Statement</b>					
Cash flow from operating activities	(125,471)	(149,644)	(55,659)	(71,872)	(251,158)
Cash flow from investing activities	(829)	(9,664)	(246)	(7,064)	(11,011)
Cash flow from financing activities	(2,446)	2,488	(1,351)	2,593	729
Cash and cash equivalents at period end	205,136	439,809	205,136	439,809	333,429
<b>Financial Ratios</b>					
Basic and diluted EPS	(2.34)	(2.56)	(0.92)	(1.32)	(4.80)
Weighted average number of shares	56,567,810	56,368,329	56,567,810	56,438,320	56,443,701
Average number of employees (FTEs)	65	101	60	99	93
Assets/equity	1.29	1.15	1.29	1.15	1.20

The interim report is unaudited.



### **Revenue**

For the first half of 2010 LCP recognized DKK 1.5 million in revenues compared to DKK 1.8 million in the same period of 2009. Revenue consists of payments under LCP's collaboration agreements.

### **Research and development costs**

For the first half of 2010, LCP's research and development costs amounted to DKK 96.0 million compared to DKK 120.4 million during the same period in 2009. The decrease is mainly due to fluctuations in activity in connection with the ongoing Phase 3 trial for LCP-Tacro<sup>TM</sup> (Stable kidney transplant patients), combined with the effect of the reduction in force that has taken place during the past 12 months.

### **Administrative expenses**

For the first half of 2010, LCP's administrative cost amounted to DKK 25.9 million compared to DKK 33.3 million during the same period in 2009. The reduction in cost is attributable to the continued focus of reducing overall cost, combined with the effect of the reduction in force that has taken place during the past 12 months.

### **One-off restructuring cost**

One-off restructuring cost mainly includes salary payments to former employees in connection with the reduction in January 2010.

### **Compensation costs**

For the first half of 2010, a total of DKK 5.0 million was recognized as share-based compensation. The cost is included in R&D and G&A. The comparable cost for 2009 was DKK 7.4 million.

In the second quarter of 2010, a total of 150,000 warrants were granted to employees at a strike price of DKK 4.87. In the second quarter of 2010, a total of 429,759 warrants have been cancelled.

As of 30 June, 2010, there were a total of 4,345,917 warrants outstanding at an average strike price of DKK 17.1. Members of the Board of Directors held 350,667 warrants at an average strike price of DKK 21.8. Members of the Executive Management held 807,572 warrants at an average strike price of DKK 12.8, while other current and former employees held 3,187,678 warrants at an average strike price of DKK 17.7.

Please refer to LCP's latest annual report for additional details on the Company's warrant programs.

### **Operating loss**

LCP's operating loss for the first half of 2010 was DKK 131.3 million compared to DKK 151.9 million in the corresponding period of 2009.

### **Financial income**

During the first half of 2010, the Company recognized net financial expenses of DKK 0.5 million compared to an income of DKK 7.6 million in the corresponding period of 2009. The decrease in financial income is a reflection of lower earned interest on a lower cash position during the period and currency loss related to the increased DKK/USD rate.



### **Net loss**

LCP's net loss for the first half of 2010 was DKK 132.2 million compared to DKK 144.3 million in the corresponding period of 2009.

### **Cash flow**

As per 30 June, 2010, the balance sheet reflects cash and cash equivalents to DKK 205.1 million compared to DKK 333.4 million as per 31 December, 2009. This represents a decrease of DKK 128.3 million primarily related to the Company's operating activities for the period.

### **Balance sheet**

As per 30 June, 2010, total assets were DKK 245.3 million compared to DKK 379.3 million at the end of 2009.

Shareholders' equity equalled DKK 190.0 million as of 30 June, 2010, compared to DKK 317.3 million at the end of 2009.

### **Accounting policies**

The interim report is prepared in compliance with International Accounting Standard No. 34 (IAS 34), "Interim Financial Reporting" and in accordance with the NASDAQ OMX Copenhagen's financial reporting requirements for listed companies.

There have been no changes in accounting policies used for the interim report compared to the accounting policies used in the preparation of LifeCycle Pharma group's annual report for 2009.

The line "one-off restructuring cost" includes major restructuring costs, mainly salary to former employees and is shown separately to facilitate the comparability of the income statement between periods.

### **Financial review**

LCP reports its financial statements in Danish Kroner (DKK), which is the functional currency of the Company and the group. Solely for the convenience of the reader, this Interim Report contains a conversion of certain DKK amounts into Euro (EUR) at a specified rate. These converted amounts should not be construed as representations that the DKK amounts actually represent such EUR amounts or could be converted into EUR at the rate indicated or at any other rate. Unless otherwise indicated, conversion herein of financial information into EUR has been made using the Danish Central Bank's spot rate on 30 June, 2010, which was EUR 1.00 = DKK 7.4488.

### **Major shareholders**

Lfi A/S	28.2%
Novo A/S	23.8%
Alta Partners	6.3%



**Grant of warrants**

At a board meeting held on 18 August, 2010, the Board of Directors decided to issue 372,000 warrants to the Board of Directors and employees of the LCP.

Of the total granted warrants, 120,000 warrants were granted to the Board of Directors, 100,000 warrants were granted to Edward E. Koval, Senior Vice President, Business Development and Strategic Corporate Development, 100,000 warrants were granted to Dr. John Weinberg, Senior Vice President, Commercial Development and Strategic Planning and 25,000 warrants were granted to Johnny Stilou, Chief Financial Officer.

Each warrant entitles the holder to subscribe one share of nominal DKK 1 in the Company against cash contribution equal to the closing price of the Company's shares at the NASDAQ OMX Copenhagen on 19 August, 2010, thus ensuring that the exercise price reflects the fair market price per share following the disclosure of the interim report for the first half of 2010.

By application of the Black-Scholes formula, the market value of the warrant program can be calculated as DKK 1.6 per warrant assuming an exercise price of DKK 4.05, equal to the closing price of the Company's share at the NASDAQ OMX Copenhagen on 17 August, 2010, based on an interest rate of 1.12% and a volatility of the Company's shares set to 48%.

The volatility is based on the Company's historical share prices since its IPO in November 2006.



### Conference Call

Today, 18 August, 2010, LCP's Management will host a conference call, at 5:30 PM CET (Denmark); 4:30 PM GMT (London), 11:30 AM ET (New York), 8:30 AM PT (San Francisco).

To access the live conference call, please dial one of the following numbers:

+45 32 71 35 00 Denmark

+44 (0)20 7138 0844 UK

+1 212 444 0896 USA

Access code 1264445

A call audio replay of the conference call will be available on [www.lcpharma.com](http://www.lcpharma.com) from tomorrow Thursday, 19 August, 2010 at 18:00 PM CET (Denmark); 17:00 PM GMT (London), 12:00 PM ET (New York), 9:00 AM PT (San Francisco), through Friday, 10 September, 2010 by dialing +45 32 71 09 13 (DK), +44 (0) 20 7111 1244 (UK) or +1 347 366 9565 (US), and entering access code 1264445#.

Additional information:

Dr. William J. Polvino  
President and CEO  
+1 (917) 647 9107  
[wjp@lcpharma.com](mailto:wjp@lcpharma.com)

The forward looking statements and targets contained herein are based on LifeCycle Pharma A/S' management's current view and assumptions. Such statements involve known and unknown risks and uncertainties that may cause actual results, performance or events to differ materially from those anticipated herein. LifeCycle Pharma A/S expressly disclaim any obligation or undertaking to update or revise any forward looking statements, targets or estimates contained in this interim report to reflect any change in events, conditions, assumptions, or circulations on which any such statements are based unless required by applicable law.

### About LifeCycle Pharma A/S (LCP)

Based in Hørsholm, Denmark, with an office in New York, LCP is an emerging specialty pharmaceutical company. Clinical development is the core of LCP's effort to develop a product portfolio which includes products for immunosuppression, specifically organ transplantation, and products to combat certain cardiovascular diseases. As a fully integrated company, LCP adapts new technologies on a fast commercial timetable. LCP's unique, patented delivery technology, MeltDose<sup>®</sup>, can improve absorption and bioavailability – at low-scale up costs – not only for a broad spectrum of drugs already on the market but also for new chemical entities. LCP has a cholesterol-lowering product, Fenoglide<sup>™</sup>, currently on the U.S. market and a diversified near- and medium-term pipeline with four product candidates in clinical trials and a number of projects in preclinical development. LCP is listed on the NASDAQ OMX Copenhagen under the trading symbol (OMX: LCP). For further information, please visit [www.lcpharma.com](http://www.lcpharma.com).



## **Executive Management's and the Board of Directors' Statement on the Interim Report**

The Executive Management and the Board of Directors have considered and adopted the Interim Report of LifeCycle Pharma A/S.

The Interim Report is prepared in accordance with International Accounting Standard No. 34 (IAS 34), "Interim Financial Reporting" and additional Danish disclosure requirements for financial reporting of listed companies.

We consider the applied accounting policies to be appropriate and, in our opinion, the Interim Report gives a true and fair view of the assets and liabilities, financial position, results of the operation and cash flow of the group for the period under review. Furthermore, in our opinion the management review includes a fair review of the development and performance of the business and the financial position of the group, together with a description of the material risks and uncertainties the group faces. The group does not face any material risks or uncertainties relating to the financial statements.

Hørsholm, 18 August, 2010

### **Executive Management**

Dr. William J. Polvino  
President and CEO

Peter G. Nielsen  
Executive Vice President

### **Board of Directors**

Paul Edick  
(Chairman)

Thomas Dyrberg  
(Deputy Chairman)

Kurt Anker Nielsen

Jean Deleage

Gérard Soula

Anders Götzsche

Mette Kirstine Agger



Interim Report  
for the 6 Months Ended 30 June, 2010  
(18 August, 2010)



Quarterly Numbers in DKK						
	Q2 2010 DKK'000	Q1 2010 DKK'000	Q4 2009 DKK'000	Q3 2009 DKK'000	Q2 2009 DKK'000	Q1 2009 DKK'000
<b>Income Statement</b>						
Revenue	871	623	182	447	1,499	349
Research and development costs	(39,625)	(56,349)	(45,740)	(43,986)	(57,604)	(62,810)
Administrative expenses	(12,773)	(13,157)	(14,713)	(14,330)	(16,357)	(16,981)
One-off restructuring cost	-	(10,894)	-	(9,489)	-	-
Operating loss	(51,527)	(79,777)	(60,271)	(67,358)	(72,462)	(79,443)
Net financial income / (expenses)	(313)	(212)	516	394	(2,105)	9,735
Loss before tax	(51,840)	(79,989)	(59,755)	(66,964)	(74,567)	(69,708)
Tax for the period	(395)	-	-	-	-	-
Net loss for the period	(52,235)	(79,989)	(59,755)	(66,964)	(74,567)	(69,708)
<b>Balance Sheet</b>						
Cash and cash equivalents	205,136	261,918	333,429	392,133	439,809	520,228
Total assets	245,345	302,353	379,269	444,915	500,455	574,148
Share capital	56,568	56,568	56,568	56,568	56,439	56,439
Total equity	189,958	240,383	317,281	373,583	436,727	507,712
Investment in property, plant and equipment	101	493	489	890	7,149	2,515
<b>Cash Flow Statement</b>						
Cash flow from operating activities	(55,659)	(69,812)	(56,800)	(44,714)	(71,872)	(77,772)
Cash flow from investing activities	(246)	(583)	(504)	(843)	(7,064)	(2,600)
Cash flow from financing activities	(1,351)	(1,095)	(1,312)	(446)	2,593	(105)
Cash and cash equivalents at period end	205,136	261,918	333,429	392,133	439,809	520,228
<b>Financial Ratios</b>						
Basic and diluted EPS	(0.92)	(1.41)	(1.06)	(1.19)	(1.32)	(1.24)
Weighted average number of shares	56,567,810	56,567,810	56,443,701	56,467,878	56,438,320	56,297,561
Average number of employees (FTEs)	60	69	77	88	99	102
Assets/equity	1.29	1.26	1.20	1.19	1.15	1.13

Interim Report  
for the 6 Months Ended 30 June, 2010  
(18 August, 2010)



Quarterly Numbers in Euro						
	Q2 2010 EUR'000	Q1 2010 EUR'000	Q4 2009 EUR'000	Q3 2009 EUR'000	Q2 2009 EUR'000	Q1 2009 EUR'000
<b>Income Statement</b>						
Revenue	117	84	24	60	201	47
Research and development costs	(5,320)	(7,565)	(6,140)	(5,905)	(7,734)	(8,432)
Administrative expenses	(1,714)	(1,766)	(1,975)	(1,924)	(2,195)	(2,280)
One-off restructuring cost	-	(1,462)	-	(1,274)	-	-
Operating loss	(6,917)	(10,709)	(8,091)	(9,043)	(9,728)	(10,665)
Net financial income / (expenses)	(42)	(29)	69	53	(283)	1,307
Loss before tax	(6,959)	(10,738)	(8,022)	(8,990)	(10,011)	(9,358)
Tax for the period	(53)	-	-	-	-	-
Net loss for the period	(7,012)	(10,738)	(8,022)	(8,990)	(10,011)	(9,358)
<b>Balance Sheet</b>						
Cash and cash equivalents	27,539	35,162	44,763	52,644	59,044	69,840
Total assets	32,937	40,591	50,917	59,730	67,186	77,079
Share capital	7,594	7,594	7,594	7,594	7,577	7,577
Total equity	25,502	32,271	42,595	50,153	58,630	68,160
Investment in property, plant and equipment	14	66	66	120	960	338
<b>Cash Flow Statement</b>						
Cash flow from operating activities	(7,472)	(9,372)	(7,625)	(6,003)	(9,649)	(10,441)
Cash flow from investing activities	(33)	(78)	(68)	(113)	(948)	(349)
Cash flow from financing activities	(181)	(147)	(176)	(60)	348	(14)
Cash and cash equivalents at period end	27,539	35,162	44,763	52,644	59,044	69,840
<b>Financial Ratios</b>						
Basic and diluted EPS	(0.12)	(0.19)	(0.14)	(0.16)	(0.18)	(0.17)
Weighted average number of shares	56,567,810	56,567,810	56,443,701	56,467,878	56,438,320	56,297,561
Average number of employees (FTEs)	60	69	77	88	99	102
Assets/equity	1.29	1.26	1.20	1.19	1.15	1.13



Income Statement		Consolidated			
(DKK'000)	YTD 2010	YTD 2009	Q2 2010	Q2 2009	Year 2009
Revenue	1,494	1,847	871	1,499	2,476
Research and development costs	(95,973)	(120,414)	(39,625)	(57,604)	(210,140)
Administrative expenses	(25,930)	(33,338)	(12,773)	(16,357)	(62,381)
One-off restructuring cost	(10,894)	-	-	-	(9,489)
<b>Operating loss</b>	<b>(131,303)</b>	<b>(151,905)</b>	<b>(51,527)</b>	<b>(72,462)</b>	<b>(279,534)</b>
Financial income	1,183	17,844	485	2,631	21,391
Financial expenses	(1,709)	(10,214)	(798)	(4,736)	(12,851)
<b>Loss before tax</b>	<b>(131,829)</b>	<b>(144,275)</b>	<b>(51,840)</b>	<b>(74,567)</b>	<b>(270,994)</b>
Tax for the period	(395)	-	(395)	-	-
<b>Net loss for the period</b>	<b>(132,224)</b>	<b>(144,275)</b>	<b>(52,235)</b>	<b>(74,567)</b>	<b>(270,994)</b>
Basic and diluted EPS	(2.34)	(2.56)	(0.92)	(1.32)	(4.80)
Weighted average number of shares	56,567,810	56,368,329	56,567,810	56,438,320	56,443,701

Statements of comprehensive income		Consolidated			
(DKK'000)	YTD 2010	YTD 2009	Q2 2010	Q2 2009	Year 2009
<b>Net loss for the period</b>	<b>(132,224)</b>	<b>(144,275)</b>	<b>(52,235)</b>	<b>(74,567)</b>	<b>(270,994)</b>
<b>Other comprehensive income:</b>					
Currency translation differences	(56)	368	(68)	63	215
<b>Other comprehensive income for the period</b>	<b>(56)</b>	<b>368)</b>	<b>(68)</b>	<b>63)</b>	<b>215)</b>
<b>Total comprehensive income for the period</b>	<b>(132,280)</b>	<b>(143,907)</b>	<b>(52,303)</b>	<b>(74,504)</b>	<b>(270,779)</b>

Interim Report  
for the 6 Months Ended 30 June, 2010  
(18 August, 2010)



Assets	Consolidated		
(DKK'000)	30 June 2010	30 June 2009	31 Dec. 2009
Patent rights and software	812	654	860
<b>Intangible assets</b>	<b>812</b>	<b>654</b>	<b>860</b>
Property, plant and equipment	15,225	22,198	18,753
Leasehold improvements	6,688	8,457	7,506
<b>Property, plant and equipment</b>	<b>21,913</b>	<b>30,655</b>	<b>26,259</b>
<b>Non-current assets</b>	<b>22,725</b>	<b>31,309</b>	<b>27,119</b>
Trade receivables	-	751	302
Other receivables	6,590	12,338	4,390
Prepayments	10,894	16,248	14,029
<b>Receivables</b>	<b>17,484</b>	<b>29,337</b>	<b>18,721</b>
<b>Cash and cash equivalents</b>	<b>205,136</b>	<b>439,809</b>	<b>333,429</b>
<b>Current assets</b>	<b>222,620</b>	<b>469,146</b>	<b>352,150</b>
<b>Assets</b>	<b>245,345</b>	<b>500,455</b>	<b>379,269</b>

Interim Report  
for the 6 Months Ended 30 June, 2010  
(18 August, 2010)



Equity & Liabilities	Consolidated		
(DKK'000)	30 June 2010	30 June 2009	31 Dec. 2009
Share capital	56,568	56,439	56,568
Share premium	1,080,263	1,079,554	1,080,263
Translation reserves	1,902	2,111	1,958
Retained earnings/loss	(948,775)	(701,377)	(821,508)
<b>Equity</b>	<b>189,958</b>	<b>436,727</b>	<b>317,281</b>
Provisions	-	10,492	-
Finance lease	11,441	16,820	14,091
<b>Non-current liabilities</b>	<b>11,441</b>	<b>27,312</b>	<b>14,091</b>
Finance lease	5,590	5,245	5,387
Trade payables	12,462	10,216	19,794
Deferred revenue	-	-	120
Other payables	25,894	20,955	22,596
<b>Current liabilities</b>	<b>43,946</b>	<b>36,416</b>	<b>47,897</b>
<b>Liabilities</b>	<b>55,387</b>	<b>63,728</b>	<b>61,988</b>
<b>Equity and liabilities</b>	<b>245,345</b>	<b>500,455</b>	<b>379,269</b>



Cash Flow Statement		Consolidated			
(DKK'000)	YTD 2010	YTD 2009	Q2 2010	Q2 2009	Year 2009
<b>Operating loss</b>	<b>(131,303)</b>	<b>(151,905)</b>	<b>(51,527)</b>	<b>(72,462)</b>	<b>(279,534)</b>
Share-based payment	4,957	7,355	1,878	3,529	13,934
Depreciation and amortization	5,006	4,891	2,513	2,594	10,455
Changes in working capital	(3,798)	(19,526)	(7,855)	(3,381)	(3,188)
<b>Cash flow from operating activities before interest</b>	<b>(125,138)</b>	<b>(159,185)</b>	<b>(54,991)</b>	<b>(69,720)</b>	<b>(258,333)</b>
Interest received	962	19,858	351	2,703	8,366
Interest paid	(532)	(10,317)	(256)	(4,855)	(1,191)
Corporate tax paid	(763)	-	(763)	-	-
<b>Cash flow from operating activities</b>	<b>(125,471)</b>	<b>(149,644)</b>	<b>(55,659)</b>	<b>(71,872)</b>	<b>(251,158)</b>
Purchase of property, plant and equipment	(594)	(9,664)	(101)	(7,149)	(11,043)
Cash transfer to restricted security deposit	(235)	-	(145)	85	32
<b>Cash flow from investing activities</b>	<b>(829)</b>	<b>(9,664)</b>	<b>(246)</b>	<b>(7,064)</b>	<b>(11,011)</b>
Installments on bank borrowings and finance lease	(2,446)	1,533	(1,351)	2,603	(1,055)
Proceeds from issuance of shares, net	-	955	-	(10)	1,784
<b>Cash flow from financing activities</b>	<b>(2,446)</b>	<b>2,488</b>	<b>(1,351)</b>	<b>2,593</b>	<b>729</b>
<b>Increase/(decrease) in cash and cash equivalents</b>	<b>(128,746)</b>	<b>(156,820)</b>	<b>(57,256)</b>	<b>(76,343)</b>	<b>(261,440)</b>
Cash and cash equivalents at beginning of period	332,066	598,735	260,466	518,749	598,735
Exchange gains/(losses) on cash and cash equivalent	219	(3,501)	329	(3,992)	(5,229)
<b>Cash and cash equivalents at end of period</b>	<b>203,539</b>	<b>438,414</b>	<b>203,539</b>	<b>438,414</b>	<b>332,066</b>
<b>Cash and cash equivalents at end of period comprise:</b>					
Restricted bank deposit	1,597	1,395	1,597	1,395	1,363
Deposit on demand and cash	203,539	438,414	203,539	438,414	332,066
	<b>205,136</b>	<b>439,809</b>	<b>205,136</b>	<b>439,809</b>	<b>333,429</b>



<b>Consolidated Equity</b>						
	<b>Number of Shares</b>	<b>Share Capital DKK'000</b>	<b>Share Premium DKK'000</b>	<b>Translation Reserves DKK'000</b>	<b>Retained Earnings DKK'000</b>	<b>Total DKK'000</b>
<b>Equity as of 1 January 2009</b>	<b>56,287,507</b>	<b>56,288</b>	<b>1,078,740</b>	<b>1,743</b>	<b>(564,448)</b>	<b>572,323</b>
Total comprehensive income				368	(144,275)	(143,907)
Warrant exercises	150,813	151	814			965
Share-based payment					7,346	7,346
<b>Equity as of 30 June 2009</b>	<b>56,438,320</b>	<b>56,439</b>	<b>1,079,554</b>	<b>2,111</b>	<b>(701,377)</b>	<b>436,727</b>
Total comprehensive income				(153)	(126,719)	(126,872)
Warrant exercises	129,490	129	709			838
Share-based payment					6,588	6,588
<b>Equity as of 31 December 2009</b>	<b>56,567,810</b>	<b>56,568</b>	<b>1,080,263</b>	<b>1,958</b>	<b>(821,508)</b>	<b>317,281</b>
Total comprehensive income				(56)	(132,224)	(132,280)
Share-based payment					4,957	4,957
<b>Equity as of 30 June 2010</b>	<b>56,567,810</b>	<b>56,568</b>	<b>1,080,263</b>	<b>1,902</b>	<b>(948,775)</b>	<b>189,958</b>

The share capital is not available for distribution, while other reserves are distributable for dividend purposes subject to the provision of the Danish Public Company Act.